Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055991 · ClinicalTrials.gov registry record · Phase 1
Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
A Phase 1 study, sponsored by Baylor Breast Care Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT00055991: Completed Phase 1 study, sponsored by Baylor Breast Care Center.
NCT00055991 is a Phase 1 study that has completed, run by Baylor Breast Care Center. The registered enrollment target is 87 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055991, a Phase 1 study, has completed, sponsored by Baylor Breast Care Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether bexarotene is effective in preventing breast cancer. PURPOSE: Randomized clinical trial to study the effectiveness of bexarotene in preventing breast cancer in women who are at genetic risk of developing breast cancer.
Interventions
- DRUG bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2001-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
What the finished NCT00055991 record still lists
NCT00055991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 1 intervention - of which bexarotene is the first listed.
NCT00055991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00055991 about?
NCT00055991 is a clinical study titled "Bexarotene in Preventing Breast Cancer in Women at Genetic Risk". RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether bexarotene is effective in preventing breast cancer. PURPOSE: Randomized clinical trial to study the effectiveness of bexarotene in preventing breast cancer i...
What is the current status of trial NCT00055991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2001-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00055991?
The interventions under investigation include: bexarotene (DRUG).
Who is sponsoring clinical trial NCT00055991?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00055991's enrollment target sits among peer trials
87 651st of 2000 higher than 1,349 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia